Payment overview · 2025
General Payments
$252.58
14 reported records · 8 companies
Healthcare provider profile · identity verified
Patrick Zimmermann, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · COLLINSVILLE, IL · NPI 1194749218
Verified facts
What the public records show
CMS Open Payments records show Patrick Zimmermann, M.D. received $252.58 in general payments during 2025 across 14 reported records.
AstraZeneca Pharmaceuticals LP accounted for 21.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Ozempic, Rybelsus, Shingrix.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $54.93 | 21.8% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $51.10 | 20.2% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $36.49 | 14.4% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $32.29 | 12.8% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $26.61 | 10.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $20.32 | 8.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.19 | 6.8% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $13.65 | 5.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $252.58 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $51.10 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $51.10 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $32.29 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $32.20 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $26.61 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $26.61 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $22.73 | 1 | 2025 |
Source payment records
|
|||||
| RELISTOR Normalized: relistor |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $20.37 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $20.32 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $20.32 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $17.19 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $17.19 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16.12 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $13.65 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 34 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 54 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 69 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 26 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
34 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
26 | 21 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
59 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
54 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
69 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1151 | 327 |
| Lisinopril | Lisinopril | 731 | 207 |
| Pantoprazole Sodium | Pantoprazole Sodium | 550 | 146 |
| Levothyroxine Sodium | Levothyroxine Sodium | 434 | 121 |
| Metoprolol Succinate | Metoprolol Succinate | 419 | 116 |
| Amlodipine Besylate | Amlodipine Besylate | 417 | 113 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 412 | 79 |
| Gabapentin | Gabapentin | 384 | 92 |
| Metformin Hcl Er | Metformin Hcl | 364 | 111 |
| Alprazolam | Alprazolam | 356 | 59 |
| Omeprazole | Omeprazole | 335 | 81 |
| Diclofenac Sodium | Diclofenac Sodium | 328 | 95 |
| Lorazepam | Lorazepam | 317 | 62 |
| Tamsulosin Hcl | Tamsulosin Hcl | 310 | 94 |
| Furosemide | Furosemide | 306 | 91 |
| Hydrochlorothiazide | Hydrochlorothiazide | 299 | 87 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 265 | 35 |
| Trazodone Hcl | Trazodone Hcl | 264 | 67 |
| Glimepiride | Glimepiride | 241 | 65 |
| Losartan Potassium | Losartan Potassium | 241 | 68 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 230 | 63 |
| Simvastatin | Simvastatin | 230 | 52 |
| Metoprolol Tartrate | Metoprolol Tartrate | 215 | 52 |
| Tramadol Hcl | Tramadol Hcl | 213 | 54 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 204 | 65 |
| Fenofibrate | Fenofibrate | 169 | 41 |
| Bupropion Xl | Bupropion Hcl | 166 | 30 |
| Celecoxib | Celecoxib | 153 | 45 |
| Meloxicam | Meloxicam | 145 | 40 |
| Escitalopram Oxalate | Escitalopram Oxalate | 141 | 35 |
| Clopidogrel | Clopidogrel Bisulfate | 137 | 38 |
| Finasteride | Finasteride | 136 | 39 |
| Duloxetine Hcl | Duloxetine Hcl | 135 | 34 |
| Buspirone Hcl | Buspirone Hcl | 131 | 23 |
| Clonazepam | Clonazepam | 130 | 21 |
| Prednisone | Prednisone | 130 | 84 |
| Metformin Hcl | Metformin Hcl | 128 | 35 |
| Carvedilol | Carvedilol | 126 | 23 |
| Allopurinol | Allopurinol | 123 | 31 |
| Eliquis | Apixaban | 121 | 28 |
| Pioglitazone Hcl | Pioglitazone Hcl | 120 | 36 |
| Sertraline Hcl | Sertraline Hcl | 117 | 30 |
| Morphine Sulfate Er | Morphine Sulfate | 113 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 108 | 15 |
| Potassium Chloride | Potassium Chloride | 108 | 33 |
| Alendronate Sodium | Alendronate Sodium | 106 | 27 |
| Montelukast Sodium | Montelukast Sodium | 102 | 32 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 98 | 25 |
| Propranolol Hcl Er | Propranolol Hcl | 95 | 24 |
| Donepezil Hcl | Donepezil Hcl | 92 | 30 |
| Ezetimibe | Ezetimibe | 90 | 26 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 90 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 90 | 26 |
| Valsartan | Valsartan | 87 | 27 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 86 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 84 | 19 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 82 | 76 |
| Mirtazapine | Mirtazapine | 82 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 81 | 63 |
| Baclofen | Baclofen | 80 | 34 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 78 | 68 |
| Ipratropium Bromide | Ipratropium Bromide | 78 | 30 |
| Quetiapine Fumarate | Quetiapine Fumarate | 74 | 14 |
| Pregabalin | Pregabalin | 73 | 16 |
| Xarelto | Rivaroxaban | 73 | 13 |
| Indapamide | Indapamide | 72 | 19 |
| Oxybutynin Chloride | Oxybutynin Chloride | 70 | 22 |
| Doxazosin Mesylate | Doxazosin Mesylate | 69 | 19 |
| Ozempic | Semaglutide | 69 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 68 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 67 | 27 |
| Metoclopramide Hcl | Metoclopramide Hcl | 65 | 17 |
| Dicyclomine Hcl | Dicyclomine Hcl | 64 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 61 | 13 |
| Naproxen | Naproxen | 60 | 12 |
| Jardiance | Empagliflozin | 59 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 59 | 38 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 58 | 11 |
| Spironolactone | Spironolactone | 57 | 18 |
| Levofloxacin | Levofloxacin | 56 | 43 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 56 | 38 |
| Atenolol | Atenolol | 55 | 12 |
| Sulindac | Sulindac | 55 | 11 |
| Meclizine Hcl | Meclizine Hcl | 54 | 20 |
| Mounjaro | Tirzepatide | 54 | 11 |
| Ondansetron Odt | Ondansetron | 54 | 16 |
| Memantine Hcl | Memantine Hcl | 53 | 15 |
| Levetiracetam | Levetiracetam | 52 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 52 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 51 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 51 | 14 |
| Fluconazole | Fluconazole | 50 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 49 | 16 |
| Testosterone Cypionate | Testosterone Cypionate | 49 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 48 | 13 |
| Ibandronate Sodium | Ibandronate Sodium | 46 | 13 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 45 | suppressed |
| Irbesartan | Irbesartan | 44 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 42 | 12 |
| Sildenafil Citrate | Sildenafil Citrate | 42 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 41 | suppressed |
| Ibuprofen | Ibuprofen | 41 | suppressed |
| Diazepam | Diazepam | 39 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 39 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 39 | 11 |
| Acyclovir | Acyclovir | 38 | 17 |
| Propranolol Hcl | Propranolol Hcl | 37 | 11 |
| Benazepril Hcl | Benazepril Hcl | 36 | 11 |
| Estradiol | Estradiol | 35 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 35 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 35 | 16 |
| Farxiga | Dapagliflozin Propanediol | 34 | 11 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 34 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 33 | 22 |
| Candesartan Cilexetil | Candesartan Cilexetil | 32 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 30 | suppressed |
| Linzess | Linaclotide | 30 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 29 | suppressed |
| Lovastatin | Lovastatin | 29 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 28 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 28 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 28 | suppressed |
| Azithromycin | Azithromycin | 27 | 23 |
| Benzonatate | Benzonatate | 27 | 13 |
| Etodolac | Etodolac | 27 | 13 |
| Famotidine | Famotidine | 27 | suppressed |
| Glipizide | Glipizide | 27 | 12 |
| Paxlovid | Nirmatrelvir/Ritonavir | 27 | 27 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 26 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 26 | suppressed |
| Ketoconazole | Ketoconazole | 26 | 18 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 26 | 21 |
| Trulicity | Dulaglutide | 26 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 25 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Entresto | Sacubitril/Valsartan | 25 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Carbamazepine | Carbamazepine | 24 | suppressed |
| Januvia | Sitagliptin Phosphate | 24 | suppressed |
| Digoxin | Digoxin | 23 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | suppressed |
| Gemfibrozil | Gemfibrozil | 21 | suppressed |
| Lansoprazole | Lansoprazole | 21 | suppressed |
| Tradjenta | Linagliptin | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 20 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 20 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Gemtesa | Vibegron | 19 | suppressed |
| Indomethacin | Indomethacin | 19 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 19 | suppressed |
| Primidone | Primidone | 19 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 18 | suppressed |
| Cephalexin | Cephalexin | 18 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 18 | suppressed |
| Levemir | Insulin Detemir | 18 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 18 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Armodafinil | Armodafinil | 17 | suppressed |
| Metolazone | Metolazone | 17 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 17 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 17 | suppressed |
| Testosterone | Testosterone | 17 | suppressed |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Modafinil | Modafinil | 15 | suppressed |
| Cholestyramine Light | Cholestyramine | 14 | suppressed |
| Clarithromycin | Clarithromycin | 14 | 11 |
| Galantamine Er | Galantamine Hbr | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 12 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Tymlos | Abaloparatide | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Minoxidil | Minoxidil | 11 | suppressed |
| Mirabegron Er | Mirabegron | 11 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
| Trospium Chloride | Trospium Chloride | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $252.58 · 14 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, Cologuard Collection Kit, FARXIGA, MOUNJARO, OTEZLA, Ozempic, RELISTOR, REPATHA, Rybelsus, SHINGRIX, XIFAXAN, YUPELRI, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error